BU-CMD Chemical Library Consortium: Fostering Collaborations between Chemists and Biologists for Translational Discovery

项目摘要和摘要 BU-CMD化学图书馆联盟： 促进化学家和生物学家之间的合作，促进翻译发现 小分子是理解生物系统的强大工具，并构成了大多数 人类疾病的治疗方法。成功地将生物活性小分子转化为安全、有效的 治疗需要化学家和生物学家的共同参与。波士顿大学研究中心 分子发现(BU-CMD)是一个将制造分子的化学家与 希望在各种疾病中测试它们。BU-CMD是一个协作纽带，将这些 联系，播种新发现，并提供进一步发展所需的关键化学支持 现有线索。该计划的目标是跨多个CTSA利用现有的BU-CMD资源 集线器，建立可扩展的分子分发基础设施，用于播种和促进协作 化学家和翻译科学家之间的研究项目。该项目的首要目标是 为具有挑战性的生物疾病领域进行先进的治疗研究。BU-CMD拥有长期的经验 在策划和公开分发各种结构复杂的小分子筛选集合中 化学类型，通过一个名为化学图书馆的独特的、本土的生物筛查联盟 财团(“CLC”)。《中图法》的独特之处在于它有能力实现新的发现，并促进有意义的 对这些发现的合作后续行动，以实现转化性药物发现。本提案描述了 通过建立一个开放的、以CTSA为基础的开放获取机制，将CLC与CTSA正式联系起来 以波士顿大学为中心的大院共享网络。拟议的U01计划将对分子进行管理 来自六个CTSA中心的合成有机化学家(波士顿大学、纽约大学、北方大学 卡罗莱纳、教堂山、加州大学洛杉矶分校、芝加哥大学和诺特大学 Dame)，并将在CLC网络内分发它们。作为这笔赠款的一部分，CLC网络将得到扩大 包括范德比尔特大学和马萨诸塞大学医学院的新翻译科学家 学校中心。最后，在BU-CMD和NCATS之间建立正式连接，以便连接 将科学家转化为在此开发的资源和技术。该联盟的目标是将 跨CTSA中心的科学资源，并在这些中心的翻译科学家之间建立新的合作 中心，并改进现有的基础设施，以发现和发展小分子疗法 疾病。

PROJECT SUMMARY AND ABSTRACT BU-CMD Chemical Library Consortium: Fostering Collaborations between Chemists and Biologists for Translational Discovery Small molecules are powerful tools for understanding biological systems, and form the foundation for most therapies of human disease. The successful translation of a bioactive small molecule into a safe, effective therapeutic requires the collective involvement of both chemists and biologists. The Boston University Center for Molecular Discovery (BU-CMD) is a laboratory that connects chemists who make molecules with biologists who wish to test them in various diseases. The BU-CMD serves as a collaborative nexus that bridges these connections, seeding new discoveries and providing the critical chemistry support required to further develop existing leads. The objective of this program is to leverage existing BU-CMD resources across multiple CTSA hubs, establishing an expandable molecule distribution infrastructure for seeding and fostering collaborative research projects between chemists and translational scientists. The overarching goal of the project is to advance curative research for challenging biological disease areas. The BU-CMD has longstanding experience in curating and openly distributing a small molecule screening collection of diverse, structurally complex chemotypes, through a unique, homegrown consortium of biological screeners called the Chemical Library Consortium ("CLC"). The CLC has been unique in its ability to enable new discoveries and foster meaningful collaborative follow-up on these discoveries toward translational drug discovery. This proposal describes the formal connection of the CLC with the CTSA through the establishment of an open access, CTSA-based compound sharing network centered at Boston University. The proposed U01 program will curate molecules from synthetic organic chemists at six CTSA hubs (Boston University, New York University, University of North Carolina, Chapel Hill, University of California Los Angeles, The University of Chicago, and University of Notre Dame) and will distribute them within the CLC network. The CLC network will be expanded as part of this grant to include new translational scientists at the Vanderbilt University and University of Massachusetts Medical School hubs. Lastly, a formal connection will be forged between the BU-CMD and NCATS in order to connect translational scientists to resources and technologies developed herein. This consortium aims to connect scientific resources across CTSA hubs, and seed new collaborations between translational scientists at these hubs, and improve upon existing infrastructure for the discovery and progression of small molecule therapies for diseases.